CN112972274A - Dental desensitizer and preparation method and application thereof - Google Patents
Dental desensitizer and preparation method and application thereof Download PDFInfo
- Publication number
- CN112972274A CN112972274A CN202110134136.1A CN202110134136A CN112972274A CN 112972274 A CN112972274 A CN 112972274A CN 202110134136 A CN202110134136 A CN 202110134136A CN 112972274 A CN112972274 A CN 112972274A
- Authority
- CN
- China
- Prior art keywords
- sodium carboxymethylcellulose
- dental
- dental desensitizer
- gelatin
- desensitizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940090898 Desensitizer Drugs 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title description 14
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims abstract description 34
- 108010010803 Gelatin Proteins 0.000 claims abstract description 26
- 239000008273 gelatin Substances 0.000 claims abstract description 26
- 229920000159 gelatin Polymers 0.000 claims abstract description 26
- 235000019322 gelatine Nutrition 0.000 claims abstract description 26
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 26
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims abstract description 26
- -1 sodium carboxymethylcellulose-modified dopamine Chemical class 0.000 claims abstract description 21
- 108700022109 ropocamptide Proteins 0.000 claims abstract description 17
- 235000013024 sodium fluoride Nutrition 0.000 claims abstract description 17
- 239000011775 sodium fluoride Substances 0.000 claims abstract description 17
- 235000010333 potassium nitrate Nutrition 0.000 claims abstract description 13
- 239000004323 potassium nitrate Substances 0.000 claims abstract description 13
- 239000011734 sodium Substances 0.000 claims abstract description 13
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 11
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 17
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 17
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 229960001149 dopamine hydrochloride Drugs 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 2
- 238000003848 UV Light-Curing Methods 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 abstract description 19
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 10
- 210000004268 dentin Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000016 photochemical curing Methods 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000007789 sealing Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 16
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 239000000606 toothpaste Substances 0.000 description 10
- 229940034610 toothpaste Drugs 0.000 description 9
- 208000002925 dental caries Diseases 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 6
- 201000002170 dentin sensitivity Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 229940091249 fluoride supplement Drugs 0.000 description 5
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 238000005299 abrasion Methods 0.000 description 4
- 238000001723 curing Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229940124380 dental desensitizing agent Drugs 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000237536 Mytilus edulis Species 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940077441 fluorapatite Drugs 0.000 description 2
- 229910052587 fluorapatite Inorganic materials 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000020638 mussel Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000000833 Periodontal Atrophy Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000004509 Tooth Discoloration Diseases 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- TUCIXUDAQRPDCG-UHFFFAOYSA-N benzene-1,2-diol Chemical group OC1=CC=CC=C1O.OC1=CC=CC=C1O TUCIXUDAQRPDCG-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- JUYQFRXNMVWASF-UHFFFAOYSA-M lithium;phenyl-(2,4,6-trimethylbenzoyl)phosphinate Chemical compound [Li+].CC1=CC(C)=CC(C)=C1C(=O)P([O-])(=O)C1=CC=CC=C1 JUYQFRXNMVWASF-UHFFFAOYSA-M 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000007719 peel strength test Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000004499 secondary dentin Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- ZBFCVKZIVHEDOE-UHFFFAOYSA-M sodium;propane-1,2,3-triol;fluoride Chemical compound [F-].[Na+].OCC(O)CO ZBFCVKZIVHEDOE-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- FVRNDBHWWSPNOM-UHFFFAOYSA-L strontium fluoride Chemical compound [F-].[F-].[Sr+2] FVRNDBHWWSPNOM-UHFFFAOYSA-L 0.000 description 1
- 229910001637 strontium fluoride Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000036367 tooth discoloration Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/415—Aminophenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a dental desensitizer, and relates to the technical field of biomedical engineering materials. The dental desensitizer comprises the following components: sodium fluoride, potassium nitrate, LL-37 antibacterial peptide, sodium carboxymethylcellulose-modified dopamine and methacrylic acid gelatin. The dental desensitizer prepared from the components disclosed by the invention has good antibacterial and dentin tubule sealing effects. The photo-curing technology is adopted to apply the anti-sensitivity paste on the surface of teeth, so that the anti-sensitivity effect of the teeth can be rapidly improved.
Description
Technical Field
The invention relates to the technical field of biomedical engineering materials, in particular to a dental desensitizer and a preparation method and application thereof.
Background
Dentine hypersensitivity is also called as hypersensitive dentin, which is an abnormal aching pain symptom caused by external stimulation such as temperature (cold and heat), chemical substances (sour and sweet), mechanical friction (abrasion and hard biting) and the like, and is characterized by rapid onset, sharp pain and short time, the first dentin hypersensitivity epidemiological investigation in China shows that the incidence of dentine hypersensitivity of adults is 8-30%, and the adult dentine hypersensitivity is a high-incidence population about 40 years old and is a common disease and a frequently encountered disease in oral clinic. Oral diseases caused by dentine hypersensitivity are more widely involved. Such as: wedge-shaped defects, periodontal atrophy tooth root exposure, tooth body trauma and dentin exposure, severe abrasion, tooth preparation, cavity preparation, tooth washing, scaling, tooth discoloration, jaw adjustment and the like.
There are many types of tooth desensitizers used clinically, and there are no specific classification criteria to guide clinical application. Depending on the main mechanism of action of the drug desensitizer, it can be classified into: inductive desensitizers, corrosive desensitizers, occlusive desensitizers, covering desensitizers, and blocking inhibitory desensitizers. For example, sodium fluoride desensitization, with 75% sodium fluoride glycerol as the major ingredient, was an earlier clinical desensitizing agent. The main principle is that fluoride ions permeate into hard tissues of teeth to be combined with calcium salt to form calcium fluorapatite deposition, so as to seal dentinal tubules or reduce the diameter of the dentinal tubules and promote secondary dentin formation. Because the permeability of restorative dentin is lower than that of primary dentin, it can protect dental pulp against irritation. However, the effect is not satisfactory through years of clinical observation.
In addition, the types of the existing anti-sensitivity toothpaste are more, and the research on all aspects of the anti-sensitivity toothpaste is greatly advanced. Because the anti-sensitive toothpaste is convenient to use and low in price, the anti-sensitive toothpaste can prevent and treat dentin hypersensitivity in daily life, and is the first choice of many patients. Common anti-sensitivity toothpastes are: sodium fluoride, sodium monofluorophosphate, potassium nitrate, strontium fluoride, oxalate and the like. Clinical observation shows that the DH has definite curative effect, and in vivo and in vitro experiments show that the DH can seal most dentinal tubules when being used for brushing teeth. Anti-sensitivity toothpaste offers the distinct advantages of ease of use and economy over other desensitization methods, but also has significant disadvantages: has slow effect, debates on the curative effect at present, has long treatment course and is not as instant as other methods.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a dental desensitizer, a preparation method and application thereof.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows: a dental desensitizer comprising the following ingredients: sodium fluoride, potassium nitrate, LL-37 antibacterial peptide, sodium carboxymethylcellulose-modified dopamine and methacrylic acid gelatin.
Potassium nitrate and sodium fluoride are functional components of a dental desensitizer, soluble potassium salt can depolarize nerve fibers and reduce the sensitivity of nerves, and free inorganic salt ions are redeposited on the surface of enamel in the form of low-solubility fluorapatite or fluorhydroxyapatite by combining with a classical remineralization medicament fluoride to promote enamel remineralization. In addition, sodium fluoride can play a role in preventing caries in toothpaste. Research shows that the fluorine-containing toothpaste has a certain caries preventing effect and can reduce the caries rate by 28 percent at most.
Antimicrobial peptides (AMPs) are a class of active polypeptides that are induced by the biological immune system. Can be used for resisting infection of various pathogens. Compared with the traditional antibiotics, AMPs have the advantages of wide antibacterial spectrum, high antibacterial activity and the like. LL-37 peptides are members of the Cathelicidin family of peptides and are known as being composed of 37 amino acids. LL-37 antibacterial peptide is expressed and secreted in various epithelial cells, immune cells, body fluid, wound secretion and the like in a human body, can exert antimicrobial activity, participates in the immune regulation of the body and promotes the wound repair, and is an active small molecular peptide with multiple functions except killing free bacteria. LL-37 antibacterial peptide can also inhibit Staphylococcus epidermidis, Pseudomonas aeruginosa, Acinetobacter baumannii, etc. in the form of biomembrane. According to the report of LL-37 antibacterial peptide and the relation between LL-37 antibacterial peptide and periodontal disease, LL-37 antibacterial peptide can effectively identify periodontal pathogenic bacteria in time, prevent and kill pathogenic bacteria from invading epithelial cells, neutralize LPS, reduce damage to periodontal tissues, chemotaxis immune cells and participate in immune defense reaction of organisms; some systemic disease patients lacking LL-37 antimicrobial peptide may be associated with severe periodontal tissue destruction.
Gelatin is a high polymer derived from collagen, has good biocompatibility and biodegradability, and is low in cost and biosafety. Therefore, gelatin is widely used in pharmaceutical and medical applications. The methacrylated gelatin is a photosensitive biological hydrogel, is obtained by the reaction of gelatin and methacrylic anhydride, has excellent biocompatibility, is rapidly cured under visible light or ultraviolet light to form a three-dimensional structure which is suitable for cell growth and has strength, and is widely applied to the fields of tissue engineering and regenerative medicine. However, the mere photocuring of methacrylated gelatin has poor adhesion and limited its use.
The natural cellulose is polysaccharide which is most widely distributed and contained in nature, and has abundant sources. Current cellulose modification technologies focus primarily on both etherification and esterification. Carboxymethylation is one of the etherification techniques. Carboxymethyl cellulose sodium (CMC-Na) is obtained after carboxymethylation of cellulose. Sodium carboxymethylcellulose (CMC-Na) is an anionic polymer compound and is white flocculent powder in appearance. It is odorless, nontoxic, tasteless, and easily soluble in water. The sodium carboxymethyl cellulose water solution is a transparent liquid, is stable to light and heat, and has strong hygroscopicity and film-forming property.
Dopamine (DOPA) is an important component of adhesion proteins secreted by marine mussels, and it contains catechol (catechol) units that play an important role in the function of adhesion of mussels to wet surfaces. The catechol-containing materials may serve as an adhesive, finishing and anchoring means, which may strongly bond a variety of inorganic and organic surfaces.
The sodium carboxymethylcellulose modified dopamine (CMC-Na-DA) has a mussel-like functional group and can increase the adhesion of a system. The system can realize injectability at the early stage of adding the cross-linking agent.
The applicant of the invention finds out through experiments that the dental desensitizer prepared from the materials has excellent effect of sealing dentinal tubules and has good antibacterial property.
Preferably, the dental desensitizer comprises the following components in parts by weight: 0.01-0.04 part of sodium fluoride, 0.1-0.5 part of potassium nitrate, 0.01-0.05 part of LL-37 antibacterial peptide, 0.03-0.08 part of sodium carboxymethylcellulose-modified dopamine and 0.8-1.2 parts of methacrylic acid gelatin.
Further preferably, the dental desensitizer comprises the following components in parts by weight: 0.02-0.03 part of sodium fluoride, 0.2-0.4 part of potassium nitrate, 0.01-0.03 part of LL-37 antibacterial peptide, 0.04-0.06 part of sodium carboxymethylcellulose-modified dopamine and 0.9-1.1 parts of methacrylic acid gelatin.
Preferably, the dental desensitizer also comprises 0.01-0.05 part of photoinitiator. The applicant has found that when a dental desensitizer is applied to the surface of a tooth by photocuring, the resistance of the tooth is rapidly increased.
In addition, the invention also discloses a preparation method of the dental desensitizer, which comprises the following steps:
(1) preparing methacrylated gelatin;
(2) preparing sodium carboxymethylcellulose modified dopamine;
(3) dissolving methacrylated gelatin and sodium carboxymethylcellulose-modified dopamine in water, then adding sodium fluoride, potassium nitrate, LL-37 antibacterial peptide and a photoinitiator, and stirring to obtain the dental desensitizer.
Preferably, in the step (1), the preparation method of the methacrylated gelatin comprises the following steps: dissolving gelatin in water, adding methacrylic anhydride, reacting for 3-5 h at 45-55 ℃, dialyzing for 5-7 days with distilled water, carrying out cutoff molecular weight of a dialysis bag to 3000-4000, and freeze-drying at-85-75 ℃ to obtain the methacrylic acid gelatin.
Preferably, in the step (2), the preparation method of the sodium carboxymethyl cellulose modified dopamine comprises the following steps: adding sodium carboxymethylcellulose into water, introducing inert gas or nitrogen, adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) after the sodium carboxymethylcellulose is completely dissolved, uniformly stirring, adding dopamine hydrochloride, adjusting the pH of a reaction system to 5-6 by using a pH regulator, reacting at room temperature for 10-15 h, dialyzing for 2-3 days by using distilled water, intercepting the molecular weight of a dialysis bag to 9000-11000, and freeze-drying at-85 to-75 ℃ to obtain the sodium carboxymethylcellulose modified dopamine.
Meanwhile, the invention also discloses a use method of the dental desensitizer, which comprises the following steps: the dental desensitizer is coated on the surface of a tooth and is cured by ultraviolet light, the curing time of the ultraviolet light is 10-30 s, and the power of an ultraviolet lamp is 1.8-2.2W/cm2。
Compared with the prior art, the invention has the beneficial effects that:
(1) sodium fluoride, potassium nitrate and LL-37 antibacterial peptide are used as functional components, so that the desensitizer has desensitizing, caries preventing and antibacterial functions.
(2) The components are compounded with the methacrylic acid gelatin and the sodium carboxymethylcellulose modified dopamine, so that the anti-sensitivity effect of teeth is synergistically improved.
(3) The preparation method is simple, the required raw materials are easy to obtain and the components are low, the problem of tooth ache and other allergy of a tooth allergy patient is solved, and the preparation method has obvious clinical significance.
(4) The desensitizer can stay on the tooth surface for a long time by a light curing method.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Examples 1 to 5
In the embodiment of the dental desensitizer, the formula of the embodiment 1-5 is shown in table 1, and the preparation method comprises the following steps:
(1) preparation of methacrylated gelatin: 10g of gelatin was dissolved in 100mL of distilled water at 50 ℃ and then 6mL of methacrylic anhydride was added, followed by reaction at 50 ℃ for 4 hours, dialyzed against distilled water for 6 days (molecular weight cut-off: 3500), and lyophilized at-80 ℃ to obtain methacrylated gelatin (GelMA).
(2) Preparing sodium carboxymethylcellulose modified dopamine: dissolving 1g of sodium carboxymethylcellulose in 100mL of deionized water, introducing nitrogen, slowly adding 575mg of EDC and 345mg of NHS into the solution after the sodium carboxymethylcellulose is completely dissolved, stirring for 20min, then adding 569mg of dopamine hydrochloride into the mixed solution, adjusting the pH of the solution to be 5-6, reacting for 12h at room temperature, dialyzing for 3 days with distilled water (molecular weight cut-off: 10000), and freeze-drying at-80 ℃ to obtain sodium carboxymethylcellulose modified dopamine (CMC-NA-DA).
(3) And dissolving GelMA, CMC-NA-DA, a photoinitiator LAP, sodium fluoride, potassium nitrate and LL-37 antibacterial peptide into 10mL of deionized water to obtain the dental desensitizer, and storing at 4 ℃ for later use.
Comparative examples 1 to 4
Comparative examples 1 to 4 are dental desensitizers, the formulations of which are shown in table 1, and the preparation methods are the same as in the examples.
Comparative example 5
A dental desensitizer which differs from example 3 only in that sodium carboxymethylcellulose-modified dopamine is replaced with dopamine.
TABLE 1 formula of dental desensitizer table (g)
Performance testing
(1) Photocuring time and peel strength testing
The examples 1 to 5 and the comparative examples 1 to 5 were respectively dropped into a 2cm × 5cm glass mold, followed by curing with ultraviolet light under the following conditions: ultraviolet light for 30s and ultraviolet lamp power of 2W/cm2. The photocuring time was recorded and the test results are recorded in table 2.
The peel strength was tested according to the GB 2792-81 standard and the test results are reported in Table 2.
TABLE 2 Cure time and Peel Strength test results
As can be seen from Table 2, the photocuring time of examples 1 to 5, comparative examples 1 to 3 and comparative example 5 was within 30 seconds, and the requirements for clinical use were satisfied with almost no difference. As for the peel strength, the peel strength of examples 1 to 5 and comparative examples 2 to 3 was maintained at 2 to 4 N.mm-1Whereas comparative example 1, comparative example 4 and comparative example 5 had no adhesion and a peel strength of 0. Comparative example 4, the CMC-NA-DA is present in excess of the system, resulting in no cure of the system.
(2) Dentinal tubule occlusion Rate test
The examples 1 to 5 and comparative examples 1 to 5 were applied to the surface of a test dentin block (3mm × 4mm × 4mm), i.e., dentin surface, with a disposable small brush, and the entire area was back and forth coated for about 15 seconds, a dental desensitizer was gently blown down, followed by curing with ultraviolet light under the photocuring conditions: ultraviolet light for 30s and ultraviolet lamp power of 2W/cm2. Each set of samples was coated with 5 pieces of dentin. The statistical method of dentin tubule occlusion rate is as follows:
and counting the total number of dentinal tubules of the dentinal modules of the blank control group under the same magnification view field, taking the counted number as a base number, calculating the total number of the unclosed dentinal tubules of each group of dentinal modules under the same magnification view field, calculating the dentinal tubule blocking rate, and recording the rate in the table 3.
TABLE 3 dentinal tubule occlusion ratio (%)
Dentinal hypersensitivity is usually caused by erosion, abrasion or abrasion, gingival recession, periodontal treatment, and the like. The hydrodynamics first presented in 1960 suggested that it was the exposed dentinal tubules that were stimulated to initiate the flow of dentinal tubule fluid that ultimately caused pain. Based on the principle, most of the desensitizing materials used clinically at present use inorganic materials, such as fluoride, oxalate and the like, to seal dentinal tubules by deposition. The dentinal tubule blocking rate is an important in vitro index for evaluating the dental desensitizer, and the industry generally requires that the dentinal tubule blocking rate of the dental desensitizer is more than or equal to 70 percent, so that the dental desensitizer belongs to an effective dental desensitizer.
As can be seen from Table 3, the dentinal tubule blocking rate of the examples 1-5 is obviously higher than that of the comparative examples 1-5, and the dentinal tubule blocking rate of the examples 1-5 is more than 75%, which indicates that the dental desensitizer prepared by the formula provided by the invention has good desensitizing effect.
(3) Fluoride ion concentration test
The dental desensitizers prepared in examples 1 to 5 and comparative examples 3 to 5 were tested for fluoride ion concentration. The test method is carried out according to the specification of 2.4.4.1 method I in YY 0623 + 2008 < determination method for dissolving out fluorine from dental material >, 1.0g of sample is weighed in a 100ml volumetric flask, 20ml of total ion intensity adjusting buffer solution is added, deionized water is added to dilute the sample to a scale, the sample is placed in (37 +/-1) DEG C water for about 5min, and the sample is detected by a fluorine ion concentration meter. Table 4 shows the results of the fluoride ion concentration test.
Table 4 fluoride ion concentration (wt.%)
| Item | Fluoride ion concentration/wt. -%) |
| Example 1 | 0.048 |
| Example 2 | 0.096 |
| Example 3 | 0.12 |
| Example 4 | 0.144 |
| Example 5 | 0.144 |
As can be seen from table 4, the fluoride ion concentrations were all greater than 0.04 wt.% and less than 0.15%. Research shows that when a small amount of sodium fluoride is added into gargle or toothpaste, caries can be reduced by 40%, and fluorine has an inhibiting effect on acid-producing bacteria. It can inhibit the storage of polysaccharide in cariogenic streptococcus cell, and influence the growth and reproduction of bacteria; inhibit exopolysaccharide synthesis by streptococcus cariogenic, and reduce adhesion of bacteria and plaque on tooth surface. In addition, fluorine can promote remineralization of enamel that has been demineralized at the initial stage of caries. However, prolonged ingestion of high doses of fluoride may lead to neurological disorders and malfunction of the endocrine system. In toothpaste or dental desensitizers, the upper limit of use for the fluoride ion concentration is 0.15%. In conclusion, the addition amount of the sodium fluoride in the range disclosed by the invention can effectively prevent caries and avoid the stimulation of fluoride to nerves.
(4) Antibacterial property test
Zone of inhibition experiments adopted standards established by the american Clinical and Laboratory Standards Institute (CLSI), detailed procedures: sterilizing a laboratory clean bench, and starting ultraviolet irradiation for 30min before operation. Then, 100. mu.L of the E.coli or S.aureus bacterial suspension was dropped onto the solid LB medium and spread on a spreading barThe surface is coated evenly. Subsequently, examples 1 to 5 and comparative examples 1 to 5 were dropped on the culture medium to form droplets of 1cm × 1cm, respectively, and cured with an ultraviolet lamp under the following conditions: ultraviolet light for 30s and ultraviolet lamp power of 2W/cm2. The dental desensitizer after photocuring is pasted on the culture medium, and after 15min, the culture dish is placed back to a biochemical incubator at 37 ℃ for inverted culture, wherein the culture time is 24 h. The medium was removed and the size of the zone of inhibition and the growth of the bacteria were observed, and three replicates of each group were taken and the average values recorded in table 5.
Table 4 antibacterial property test results
As can be seen from Table 4, comparative examples 1 to 3 had no antibacterial activity, while examples 1 to 5 had good antibacterial activity against both Staphylococcus aureus (gram-positive) and Escherichia coli (gram-negative). By integrating the test results of dentinal tubule occlusion rate, fluoride ion concentration, antibacterial property and the like, examples 2 to 4 are relatively better formulas.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (9)
1. A dental desensitizer comprising the following components: sodium fluoride, potassium nitrate, LL-37 antibacterial peptide, sodium carboxymethylcellulose-modified dopamine and methacrylic acid gelatin.
2. A dental desensitizer according to claim 1, comprising the following ingredients in parts by weight: 0.01-0.04 part of sodium fluoride, 0.1-0.5 part of potassium nitrate, 0.01-0.05 part of LL-37 antibacterial peptide, 0.03-0.08 part of sodium carboxymethylcellulose-modified dopamine and 0.8-1.2 parts of methacrylic acid gelatin.
3. A dental desensitizer according to claim 2, comprising the following ingredients in parts by weight: 0.02-0.03 part of sodium fluoride, 0.2-0.4 part of potassium nitrate, 0.01-0.03 part of LL-37 antibacterial peptide, 0.04-0.06 part of sodium carboxymethylcellulose-modified dopamine and 0.9-1.1 parts of methacrylic acid gelatin.
4. A dental desensitizer according to claim 2, further comprising 0.01 to 0.05 parts of a photoinitiator.
5. A method of preparing a dental desensitizer according to claim 4, including the steps of:
(1) preparing methacrylated gelatin;
(2) preparing sodium carboxymethylcellulose modified dopamine;
(3) dissolving methacrylated gelatin and sodium carboxymethylcellulose-modified dopamine in water, then adding sodium fluoride, potassium nitrate, LL-37 antibacterial peptide and a photoinitiator, and stirring to obtain the dental desensitizer.
6. A method of preparing a dental desensitizer according to claim 5, wherein in step (1), methacrylated gelatin is prepared by: dissolving gelatin in water, adding methacrylic anhydride, reacting for 3-5 h at 45-55 ℃, dialyzing for 5-7 days with distilled water, carrying out cutoff molecular weight of a dialysis bag to 3000-4000, and freeze-drying at-85-75 ℃ to obtain the methacrylic acid gelatin.
7. The method of preparing a dental desensitizer according to claim 5, wherein in step (2), the sodium carboxymethylcellulose-modified dopamine is prepared by: adding sodium carboxymethylcellulose into water, introducing inert gas or nitrogen, adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide after the sodium carboxymethylcellulose is completely dissolved, uniformly stirring, adding dopamine hydrochloride, adjusting the pH of a reaction system to 5-6 by using a pH regulator, reacting for 10-15 h at room temperature, dialyzing for 2-3 days by using distilled water, and freeze-drying at-85 to-75 ℃ to obtain the sodium carboxymethylcellulose modified dopamine.
8. A method of use of a dental desensitizer according to claim 4, wherein the dental desensitizer is applied to the tooth surface and subsequently cured with UV light.
9. The use of claim 8, wherein the UV curing time is 10-30 s, and the power of the UV lamp is 1.8-2.2W/cm2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110134136.1A CN112972274A (en) | 2021-01-29 | 2021-01-29 | Dental desensitizer and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110134136.1A CN112972274A (en) | 2021-01-29 | 2021-01-29 | Dental desensitizer and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112972274A true CN112972274A (en) | 2021-06-18 |
Family
ID=76345944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110134136.1A Pending CN112972274A (en) | 2021-01-29 | 2021-01-29 | Dental desensitizer and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112972274A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117990728A (en) * | 2024-04-07 | 2024-05-07 | 北京大学口腔医学院 | In vitro efficacy evaluation device and method for protein denaturation blocking type tooth desensitizer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688281A (en) * | 2002-08-05 | 2005-10-26 | 高露洁-棕榄公司 | Dentinal desensitizing toothpaste |
| CN107822901A (en) * | 2017-11-23 | 2018-03-23 | 山东朱氏药业集团有限公司 | A kind of dentistry desensitizer |
| CN109453193A (en) * | 2018-09-01 | 2019-03-12 | 济南秦鲁药业科技有限公司 | A kind of desensitizing dental gel and preparation method |
| CN110917392A (en) * | 2019-12-31 | 2020-03-27 | 广州贝奥吉因生物科技股份有限公司 | Hemostatic and antibacterial hydrogel with adhesiveness and preparation method thereof |
-
2021
- 2021-01-29 CN CN202110134136.1A patent/CN112972274A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688281A (en) * | 2002-08-05 | 2005-10-26 | 高露洁-棕榄公司 | Dentinal desensitizing toothpaste |
| CN107822901A (en) * | 2017-11-23 | 2018-03-23 | 山东朱氏药业集团有限公司 | A kind of dentistry desensitizer |
| CN109453193A (en) * | 2018-09-01 | 2019-03-12 | 济南秦鲁药业科技有限公司 | A kind of desensitizing dental gel and preparation method |
| CN110917392A (en) * | 2019-12-31 | 2020-03-27 | 广州贝奥吉因生物科技股份有限公司 | Hemostatic and antibacterial hydrogel with adhesiveness and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 姚佳等: "抗菌肽LL-37在几种常见口腔疾病中的作用", 《医学综述》 * |
| 杜凤芝等: "《口腔内科学》", 30 June 2016, 中国医药科技出版社 * |
| 韩延华等: "《常见病家庭医疗手册》", 30 June 2002, 黑龙江科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117990728A (en) * | 2024-04-07 | 2024-05-07 | 北京大学口腔医学院 | In vitro efficacy evaluation device and method for protein denaturation blocking type tooth desensitizer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3600220B1 (en) | Polyphenols/peg based hydrogel system for a dental varnish | |
| CN111989081B (en) | Oral care composition for promoting gingival health | |
| CN110585062B (en) | Hyaluronic acid oral care composition and preparation method and application thereof | |
| CN111936115A (en) | Oral care composition for promoting gum health | |
| CN111936114A (en) | Oral care composition for promoting gum health | |
| CN111989083A (en) | Oral care composition for promoting gum health | |
| CN113144002B (en) | Probiotic composition for maintaining oral health and application thereof | |
| IE20170230A1 (en) | Gel comprising chlorhexidine | |
| JP6315615B2 (en) | Treatment of inflammatory diseases and improved oral hygiene using metal modulators with methylsulfonylmethane as a transport enhancer | |
| WO2022142383A1 (en) | Oral product containing hyaluronic acid, and preparation method therefor | |
| CN113679632B (en) | Application of antibacterial peptide compound DM80Bu20 in preparation of antibacterial toothpaste | |
| Satyanegara et al. | An invitro study of caries arresting effect of propolis fluoride and silver diamine fluoride on dentine carious lesions | |
| CN112972274A (en) | Dental desensitizer and preparation method and application thereof | |
| AU2016381178B2 (en) | Mucin coated silica for bacterial aggregation | |
| JPS59225109A (en) | Composition for oral cavity application | |
| CN116650493A (en) | Use of escitalopram or derivatives thereof for preventing and/or ameliorating gum damage caused by cigarette smoke and method for achieving the use | |
| CN113546034A (en) | Antibacterial toothpaste suitable for soft water | |
| CN114028239B (en) | Root canal disinfection paste and preparation method thereof | |
| CN112194588B (en) | Use of a naphthalene ring compound in the preparation of products for preventing and treating oral bacteria | |
| Abdallah et al. | “Release characterization and biological effect of Glass Ionomer Functionalized with Two Different Chlorohexidine Derivatives” | |
| CN110787138A (en) | Preparation method of double anti-caries medicine and preparation of double anti-caries medicine | |
| CN116440036B (en) | Tooth-strengthening toothpaste capable of repairing, whitening, protecting gingiva and preparing method thereof | |
| Nair et al. | Evaluation of effect of vitamin C on streptococcus mutans induced secondary caries: An In vitro study | |
| KR101617845B1 (en) | Composition for preventing and improving periodontal disease | |
| Shoaeb et al. | Assessment of Antibacterial Effect, Solubility, Fluoride Ion Release and Compressive Strength of Glass Ionomer Containing Chlorhexidine versus Conventional Glass Ionomer Restorative Material (In-vitro study) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210618 |
|
| RJ01 | Rejection of invention patent application after publication |